# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
American leaders push for lower drug prices, highlighting recent legislation and widespread support for affordable medications....
- Reuters
https://www.usatoday.com/story/opinion/2024/07/02/biden-sanders-prescription-drug-cost-ozempic-wegovy/74232827007/
Cantor Fitzgerald analyst Louise Chen reiterates Novo Nordisk (NYSE:NVO) with a Overweight and maintains $160 price target.
2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editin...
Novo Nordisk, Carvana, And Now Rivian We've had bullish moves in three stocks we had bullish bets on this week, and since...